Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$0.42 - $0.57 $15,259 - $20,709
36,333 Added 106.34%
70,500 $39,000
Q3 2023

Nov 13, 2023

SELL
$0.51 - $1.05 $102,045 - $210,094
-200,090 Reduced 85.41%
34,167 $20,000
Q2 2023

Aug 11, 2023

SELL
$0.53 - $1.03 $76,775 - $149,205
-144,860 Reduced 38.21%
234,257 $134,000
Q1 2023

May 12, 2023

SELL
$0.64 - $3.15 $26,456 - $130,214
-41,338 Reduced 9.83%
379,117 $266,000
Q4 2022

Feb 10, 2023

BUY
$2.03 - $4.28 $380,929 - $803,142
187,650 Added 80.6%
420,455 $950,000
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $362,808 - $613,433
119,345 Added 105.19%
232,805 $744,000
Q2 2022

Aug 12, 2022

SELL
$3.17 - $6.17 $717,859 - $1.4 Million
-226,454 Reduced 66.62%
113,460 $431,000
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $1.41 Million - $4.66 Million
339,914 New
339,914 $1.83 Million
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $340,841 - $579,399
-31,472 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $10,194 - $14,695
780 Added 2.54%
31,472 $565,000
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $114,830 - $141,800
6,951 Added 29.28%
30,692 $526,000
Q1 2021

May 17, 2021

BUY
$16.56 - $25.46 $393,150 - $604,445
23,741 New
23,741 $474,000
Q4 2020

Feb 16, 2021

SELL
$15.77 - $19.03 $258,959 - $312,491
-16,421 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$16.59 - $24.79 $22,379 - $33,441
-1,349 Reduced 7.59%
16,421 $272,000
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $299,602 - $416,528
17,770 New
17,770 $411,000
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $165,015 - $318,855
-11,404 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $43,166 - $62,886
-2,720 Reduced 19.26%
11,404 $246,000
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $92,988 - $199,448
5,499 Added 63.76%
14,124 $257,000
Q2 2018

Aug 15, 2018

BUY
$46.25 - $104.45 $398,906 - $900,881
8,625 New
8,625 $421,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.